CVS Launches Community Pharmacies to Enhance Access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CVS?
Source: Newsfilter
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 71.820
Low
91.00
Averages
96.71
High
105.00
Current: 71.820
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Launches Community Pharmacies to Enhance Access
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
CVS Health to Open Pharmacy-Only Locations in Multiple Communities in 2026, Alongside New Site in Chicago
- Pharmacy Locations: CVS Health is planning to open pharmacy-only locations in several communities in 2026, in addition to a new site in Chicago.
- Community Focus: The initiative aims to enhance access to pharmacy services in various neighborhoods, reflecting a commitment to community health.
See More
CVS Health Launches Its First Pharmacy-Only Location in Chicago
CVS Pharmacy Launch: CVS has opened its first pharmacy-only location in Chicago, marking a new approach to its retail strategy.
Focus on Accessibility: The new pharmacy aims to enhance accessibility to pharmaceutical services for the local community.
Innovative Services: This location will offer a range of services tailored to meet the needs of patients, including medication management and consultations.
Expansion Plans: CVS plans to evaluate the success of this model for potential expansion to other urban areas in the future.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
CVS Launches Community Pharmacies to Enhance Access
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.
See More
Eli Lilly's GLP-1 Pill Approval Marks New Weight Loss Market Entry
- Regulatory Milestone: The FDA's approval of Eli Lilly's GLP-1 pill, Foundayo, represents a significant advancement for the company in the weight-loss medication market, setting the stage for competition with Novo Nordisk's Wegovy and altering market dynamics.
- Pricing Strategy: Foundayo is priced at $25 per month with insurance or between $149 and $349 out-of-pocket, aiming to attract a broader patient base, particularly appealing to seniors, thereby expanding the market for weight-loss drugs.
- Global Market Expansion: Lilly plans to seek approval for Foundayo in over 40 countries within the next year, leveraging its small molecule nature to enable global production and distribution without cold-chain constraints, enhancing its competitive edge.
- Sales Projections: Analysts estimate Foundayo's sales could reach $14.79 billion by 2030, although lower than Zepbound's $24.68 billion, it still indicates strong market potential and is seen as a key factor for Eli Lilly's stock recovery.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
CVS Health to Open Pharmacy-Only Locations in Multiple Communities in 2026, Alongside New Site in Chicago
- Pharmacy Locations: CVS Health is planning to open pharmacy-only locations in several communities in 2026, in addition to a new site in Chicago.
- Community Focus: The initiative aims to enhance access to pharmacy services in various neighborhoods, reflecting a commitment to community health.
See More
CVS Health Launches Its First Pharmacy-Only Location in Chicago
CVS Pharmacy Launch: CVS has opened its first pharmacy-only location in Chicago, marking a new approach to its retail strategy.
Focus on Accessibility: The new pharmacy aims to enhance accessibility to pharmaceutical services for the local community.
Innovative Services: This location will offer a range of services tailored to meet the needs of patients, including medication management and consultations.
Expansion Plans: CVS plans to evaluate the success of this model for potential expansion to other urban areas in the future.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
